Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.
Vatzia E. et al, (2024), NPJ Vaccines, 9
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine.
Wee EG-T. et al, (2024), Vaccines (Basel), 12
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS Pathog, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Bissett C. et al, (2024), NPJ Vaccines, 9
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Drury RE. et al, (2024), Nat Commun, 15
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nat Commun, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P. et al, (2023), Nat Immunol, 24, 1161 - 1172
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Hotez PJ. et al, (2023), BMJ Glob Health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Excler J-L. et al, (2023), BMJ Glob Health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Privor-Dumm L. et al, (2023), BMJ Glob Health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Zhang P. et al, (2023)
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
Saunders JE. et al, (2023), EBioMedicine, 90
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA. et al, (2023), Lancet Infect Dis, 23, 295 - 306
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Vatzia E. et al, (2023), NPJ Vaccines, 8
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome Open Res, 8